Inventor · disambiguated record
Yuichiro Tabunoki
Also filed as: TABUNOKI YUICHIRO
2 granted patents·12 pending applications·11 citations·filing 2003–2020
51Inventor score
Top patents by PatentIndex Score
14 records- 0181US8575153B2Pyridine-3-carboxyamide derivativeKITAMURA TAKAHIRO·Filed 2009·Granted Nov 5, 2013·11 cites·6 claims
- 0247US2007142281A1Preventives/remedies for myeloma tumor and method for diagnosing the sameKOWA CO·Filed 2006·Application pending·0 cites
- 0346US2022162206A1Novel azaindole derivativeKOWA CO·Filed 2020·Application pending·0 cites
- 0445US7745154B2Preventives/remedies for myeloma tumor and method of diagnosing the sameKOWA CO·Filed 2003·Granted Jun 29, 2010·0 cites·10 claims
- 0544US2010075972A1Agent for treatment of multiple sclerosisKOWA CO·Filed 2008·Application pending·0 cites
- 0640US2009281106A1Prophylactic and/or therapeutic method for rheumatoid arthritisKOWA CO·Filed 2006·Application pending·0 cites
- 0740US2009131443A1Method for prevention and/or treatment of rheumatoid arthritisKOWA CO·Filed 2006·Application pending·0 cites
- 0839US2009042901A1Agent for prevention/therapy of disease caused by keratinocyte growthKOWA CO·Filed 2006·Application pending·0 cites
- 0939US2010120732A1Agent for prevention and/or treatment of systemic lupus erythematosusKOWA CO·Filed 2008·Application pending·0 cites
- 1039US2009018121A1Preventive and/or therapeutic agent for rheumatoid arthritisKOWA CO·Filed 2006·Application pending·0 cites
- 1139US2010234407A1Preventives/remedies for myeloma tumor and method for diagnosing the sameKOWA CO·Filed 2010·Application pending·0 cites
- 1237US2009203701A1Prophylactic and/or therapeutic agent for rheumatoid arthritisKOWA CO·Filed 2007·Application pending·0 cites
- 1337US2007021418A1Method of inhibiting production of osteopontinKOWA CO·Filed 2004·Application pending·0 cites
- 1437US2007270431A1Preventive and/or Therapeutic Medicine for Rheumatoid ArthritisKOWA CO·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →